Assessment of Handgrip Strength in Adults With Inflammatory Bowel Disease

Status Not yet recruiting

Clinical Trial Summary

Inflammatory bowel disease (IBD) is a chronic disease, which causes inflammation of the gut. People with this disease are often poorly nourished. Problems caused by poor nutrition such as poor wound healing can be reduced if it is recognised and treated early.

When people with IBD attend outpatients clinic with their IBD specialist they are weighed and their BMI calculated to indicate if they are poorly nourished. Weight and BMI may not always provide a good assessment of how well nourished a person is because it does not describe the amount of muscle in the body in proportion to fat. A person with a low or decreasing amount of muscle but a normal or high BMI is at risk of nutritional problems. Measuring the amount of muscle someone with IBD has in routine practice poses a challenge to clinicians due to time constraints. One-way of measuring the amount of muscle a person has is to measure their muscle strength. This can be measured by recording the strength of a person's handgrip. Handgrip strength can be measured using a hand-held device called a dynamometer.

This study aims to test whether it is possible to measure the handgrip strength of people with IBD attending outpatient's clinic. It also aims to test how the measure obtained compares with other methods of assessing whether someone is malnourished and their health. People with a diagnosis of IBD who are aged 18 or older and who are scheduled to attend IBD outpatients clinic in one hospital will be asked to take part in the study. Their handgrip strength will be measured each time they attend clinic over a nine-month period in addition to other information about their health and nutritional state. This study forms part of a Masters in Research being undertaken with The University of Southampton.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02950779
Study type	Observational
Source	University of Southampton
Contact	Catherine Foley, Miss
Phone	02381206072
Email	catherine.foley@uhs.nhs.uk
Status	Not yet recruiting
Phase	N/A
Start date	October 2016
Completion date	October 2017

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03278912` - Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
Terminated	`NCT00061282` - Clotrimazole Enemas for Pouchitis in Children and Adults	Phase 1/Phase 2
Recruiting	`NCT05579392` - A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis	N/A
Completed	`NCT03264690` - Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients
Recruiting	`NCT02861053` - Inflammatory Bowel Disease : Could a Regular Physical Activity Reduce Patients Fatigue ?	N/A
Recruiting	`NCT02275676` - Resting Energy Expenditure and Nutritional Status in IBD	N/A
Completed	`NCT02503696` - Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)	N/A
Completed	`NCT02161640` - Vascular Dysfunction in Paediatric IBD	N/A
Completed	`NCT02197780` - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD	N/A
Completed	`NCT01860651` - Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease	N/A
Completed	`NCT01933867` - Water-aided Colonoscopy in Inflammatory Bowel Disease Patients	N/A
Completed	`NCT01852760` - Assessment of Disease Activity in Ulcerative Colitis by Endoscopic Ultrasound	N/A
Completed	`NCT01688557` - Trial on Innovative Technologies in Colonoscopy	N/A
Completed	`NCT01676324` - FOCUS: The Future of Fecal Calprotectin Utility Study for the Diagnosis and Management of Inflammatory Bowel Disease (IBD)	N/A
Completed	`NCT01666535` - Infliximab IBD Influenza Vaccine Study	N/A
Completed	`NCT01692743` - Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)	Phase 3
Completed	`NCT01557387` - Real-time Diagnosis of Pseudopolyps During Colonoscopy
Completed	`NCT01981616` - Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab	Phase 1
Completed	`NCT01221818` - A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects	Phase 1
Completed	`NCT01476995` - Prognostic Indicators as Provided by the EPIC ClearView	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.